Fincchta
Publications
| Date | YTA | Active Substance /Method | Intended use | Recommendation |
|---|---|---|---|---|
| 1/2023 | HUS | Pembrolizumab (Keytruda) | Neoadjuvant therapy in the treatment of triple-negative breast cancer | Yes |
| 1/2023 | HUS | Sacituzumab govitecan (Trodelvy®) | Advanced triple-negative breast cancer | Yes |
| 1/2023 | HUS | Dabrafenib (Tafinlar) + Trametinib (Mekinist) -yhdistelmähoito | Treatment of advanced BRAF V600 mutation-positive non-small cell lung cancer in adult patients | No |
| 1/2023 | TAYS | Pembrolizumab (Keytruda®) | Locally advanced or metastatic triple-negative breast cancer | Yes |
| 1/2023 | TAYS | Sacituzumab govitecan (Trodelvy®) | Advanced triple-negative breast cancer | Yes |
| 1/2023 | TAYS | Nivolumab (Opdivo) | Adjuvant treatment of esophageal cancer or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and surgery | Yes |
| 3/2023 | HUS | Nivolumab (Opdivo) + oxaliplatin-capecitabine (XELOX) -combination therapy | First-line treatment for adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma with a tumor PD-L1 expression CPS score of at least 5 | Yes |
| 3/2023 | HUS | Nivolumab (Opdivo) + fluoropyrimidine- and platinum-based chemotherapy combination therapy | First-line treatment for adults with unresectable, advanced, recurrent, or metastatic esophageal squamous cell carcinoma with tumor cell PD-L1 expression of at least 1% | Yes |
| 3/2023 | HUS | Pembrolizumab (Keytruda) | As adjuvant therapy for patients with stage 2C melanoma (indication extension) | Yes |
| 3/2023 | OYS | Renal denervation | Treatment of resistant hypertension | Yes |
| 3/2023 | HUS | Aptima HPV Genotype Reflex Test | Detects HPV 16 and HPV 18/45 virus types separately | Yes |
| 3/2023 | TAYS | Esketamine | Treatment-resistant depression | No |
| 3/2023 | TYKS | Nivolumab (Obdivo®) | Nivolumab (Opdivo®) – monotherapy as adjuvant treatment for adult patients with muscle-invasive urothelial carcinoma | Yes |
| 4/2023 | HUS | Trastuzumab-deruxtecan (Enhertu®) | Advanced HER2-positive breast cancer second-line treatment | Yes |
| 4/2023 | HUS | Cabozantinib (Cabometyx®) | Third-line treatment for patients with treatment-resistant osteosarcoma or Ewing’s sarcoma | Yes |
| 4/2023 | HUS | Ruxolitinib (Jakavi®) | Treatment of severe steroid-resistant graft-versus-host disease in children | Yes |
| 4/2023 | HUS | Mepolizumab (Nucala®) | Adjunctive treatment for adult patients with hypereosinophilic syndrome (HES) when disease control is inadequate and no non-hematologic secondary cause has been identified. | Yes |
| 4/2023 | HUS | Mepolizumab (Nucala®) | Adjunctive treatment for patients with relapsing-remitting or treatment-resistant eosinophilic granulomatosis with polyangiitis (EGPA). | Yes |
| 4/2023 | HUS | Imlifidase (Idefirix) | Desensitization therapy for highly sensitized adult kidney transplant patients with a positive crossmatch against deceased donor tissues. | Yes |
| 5/2023 | HUS | Tebentafusp | Treatment of choroidal melanoma | Yes |
| 5/2023 | TAYS | Trastuzumab-deruxtecan (Enhertu®) | Metastatic HER2-positive gastric and gastroesophageal junction adenocarcinoma, second-line treatment | No |
| 5/2023 | TYKS | Amivantamab (Rybrevant) | Non-small cell lung cancer | No |
| 8/2023 | TAYS | Spesolimab | Monotherapy for the treatment of flares in generalized pustular psoriasis | No |
| 8/2023 | TAYS | Luspatersept | Red blood cell transfusion-dependent anemia associated with myelodysplastic syndrome | No |
| 8/2023 | TYKS | Axicaptagene ciloleusel (Yescarta) | CAR T-cell therapy: axicabtagene ciloleucel (Yescarta®) indication extension for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). | Yes |
| 8/2023 | OYS | Nivolumab | Neoadjuvant treatment for resectable NSCLC (non-small cell lung cancer) | Yes |
| 9/2023 | HUS | Peginterferon alfa-2a (Pegasys®) | Pegylated interferon alfa-2a (Pegasys®) for the treatment of pediatric myeloproliferative disease (polycythemia vera and essential thrombocythemia). | Yes |
| 9/2023 | HUS | Axicaptagene ciloleusel (Yescarta®) | Treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) when the disease has relapsed within 12 months of completing first-line therapy. | Yes |
| 10/2023 | OYS | Atezolizumab | 50% and whose disease has not progressed after platinum-based chemotherapy.>As adjuvant therapy after complete tumor resection for adults with stage II–IIIa NSCLC diagnosis, whose tumors have PD-L1 expression >50% and whose disease has not progressed after platinum-based chemotherapy. | Yes |
| 11/2023 | HUS | Sasituzumab govitecan (Trodelvy®) | For well-functioning patients (WHO 0-1) with metastatic or locally advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have previously received 2–4 lines of chemotherapy (including a taxane as the first-line treatment, at least one hormone therapy, and one CDK4/6 inhibitor treatment line). | Yes |
| 11/2023 | HUS | Trastuzumab deruxtecan (Enhertu) | For well-functioning patients (WHO 0-1) with metastatic hormone receptor-positive or -negative breast cancer who have previously received 1–2 lines of chemotherapy and whose tumor shows low-level HER2 positivity based on immunohistochemical analysis (HER2 1+ or 2+ and ISH-negative = HER2-low). | Yes |
| 11/2023 | HUS | Symani Surgical System – microanastomosis robot | Patients undergoing reconstructive microsurgery where a microsurgical vascular, nerve, or lymphatic anastomosis is planned, particularly those with anastomosed structures less than 2 mm in diameter. | No |
| 11/2023 | HUS | Mepolizumab and benralizumab | IL-5 (mepolizumab) and IL-5R (benralizumab) antibodies for eosinophilic pneumonia or bronchopulmonary aspergillosis | Yes |
| 1/2024 | HUS | Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine | First-line treatment for advanced urothelial carcinoma | Yes |
| 1/2024 | TAYS | Atezolizumab | Adjuvant treatment for non-small cell lung cancer (NSCLC) when PD-L1 expression is at least 50% | Yes |
| 1/2024 | TAYS | Amoxicillin – clavulanic acid / Xilmac | Antibiotic prophylaxis, infection treatment | Yes |
| 1/2024 | TAYS | Nivolumab | Combination therapy with platinum-based chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC) in adults whose tumor PD-L1 expression is at least 1%. | Yes |
| 1/2024 | HUS | Dostarlimab in combination therapy with carboplatin and paclitaxel | For the treatment of primary advanced or recurrent dMMR/MSI-H endometrial cancer. | Yes |
| 1/2024 | TYKS | Pembrolizumab (Keytruda) | Pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-based chemotherapy as first-line treatment for HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults. | Yes |
| 1/2024 | TYKS | Pembrolizumab (Keytruda) | Pembrolizumab (Keytruda) in combination with fluoropyrimidine-, platinum-based chemotherapy, and trastuzumab for locally advanced or metastatic HER2-positive gastroesophageal junction adenocarcinoma. | Yes |
| 2/2024 | HUS | Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) therapy for pancreatic tumors | Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) therapy for pancreatic tumors | Yes |
| 4/2024 | HUS | A-NRP (Abdominal Normothermic Regional Perfusion) in organ transplantation | Abdominal normothermic perfusion in organ transplantation | Yes |
| 4/2024 | HUS | Tisagenlecleusel (Kymriah) | Tisagenlecleucel (Kymriah) for adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more lines of systemic therapy. | Yes |
| 4/2024 | HUS | Pembrolizumab in combination with trastuzumab and fluoropyrimidine-platinum-based combination chemotherapy. | First-line treatment for adults with unresectable, advanced, recurrent, or metastatic HER2-positive gastroesophageal junction adenocarcinoma, with a tumor PD-L1 ligand expression CPS score of at least 1. | Yes |
| 4/2024 | HUS | Tenecteplase (Metalyse®) | As a thrombolytic treatment for acute ischemic stroke. | Yes |
| 5/2024 | HUS | Bulevirtide (Hepcludex®) | In the treatment of D hepatitis. | Yes |
| 5/2024 | HUS | Pembrolizumab as adjuvant therapy for the treatment of radically resected high-risk clear cell renal cell carcinoma. | For the treatment of radically resected high-risk clear cell renal cell carcinoma. | Yes |
| 6/2024 | HUS | Teclistamab | Teclistamab for the treatment of relapsed multiple myeloma. | Yes |
| 6/2024 | HUS | Osilodrostat | Osilodrostat for the treatment of severe, life-threatening hypercortisolism. | Yes |
| 6/2024 | HUS | ECMO | ECPR (Extracorporeal Cardiopulmonary Resuscitation) ECMO-assisted resuscitation. | Yes |
| 6/2024 | HUS | Genetic testing | Expansion of the indication for genetic testing in breast cancer patients. | Yes |
| 9/2024 | OYS | Tafasitamab-lenalidomid | Relapsed and treatment-refractory diffuse B-cell lymphoma in patients who are not candidates for autologous stem cell transplantation. | No |
| 10/2024 | HUS | TS-BRCA1/2 mutation testing requirement | TS-BRCA1/2 mutation testing requirement in metastatic castration-resistant prostate cancer (MCRPC). | Yes |
| 10/2024 | KYS | Farisimab | Treatment of retinal vein occlusion. | Yes |
| 11/2024 | HUS | Combination therapy of pembrolizumab and lenvatinib | In anaplastic and poorly differentiated thyroid cancer. | Yes |
| 11/2024 | HUS | Palopegteriparatide | In the treatment of chronic hypoparathyroidism in adults. | Yes |
| 11/2024 | HUS | Upadacitinib | In the treatment of severe, drug-resistant inflammatory bowel disease (IBD) in children (Ulcerative colitis, Crohn’s disease, or undifferentiated IBD). | Yes |
| 11/2024 | HUS | ION robot bronchoscope (Surgical Intuitive) 3 | Patients with imaging or follow-up findings indicating a lung change that requires tissue sample collection for diagnosis and treatment planning. | Yes |
| 12/2024 | HUS | Letermovir | Prevention of cytomegalovirus (CMV) reactivation and virus-induced disease in CMV-seropositive pediatric patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). | Yes |
| 9/2024 | TAYS | Inhaled amikacin (Arikayce) | Refractory pulmonary mycobacterial infection | Yes |
| 9/2024 | HUS | Naldemedine (Rizmoic) | Treatment of opiate constipation | Yes |
| 10/2024 | TAYS | Palopegteriparatide (Yorvipath) | Chronic hypoparathyroidism | No |
| 12/2024 | TAYS | Dextrazocan (Savene) | Cardioprotective drug in conjunction with the use of anthracyclines | Yes |
| 2/2025 | OYS | Nivolumab-ipilimumab | In the treatment of non-small cell lung cancer (PD-L1 < 1% group) | Yes |
| 2/2025 | HUS | Infliximab (s.c.) | In the treatment of pediatric IBD and rheumatoid arthritis – off-label use | Yes |
| 2/2025 | HUS | Pembrolizumab (Keytruda) | Locally advanced stage III-IVA (FIGO 2014) cervical cancer during chemoradiotherapy and as maintenance therapy after chemoradiotherapy | Yes |
| 2/2025 | HUS | EFTR and Ovesco-FTRD | Endoscopic full thickness resection (EFTR): Ovesco Full thickness resection device (Ovesco-FTRD) | Yes |
| 3/2025 | HUS | Symani Surgical System Microanastomosis Robot (Reassessment) | Reconstructive microsurgery patients | No |
| 5/2025 | HUS | Intravascular laser (The Philips Laser System – Nexcimer) | Opening of blocked calcified coronary arteries and peripheral arteries | Yes |